No Data
Revenues Not Telling The Story For Xiangxue Pharmaceutical Co.,Ltd. (SZSE:300147) After Shares Rise 101%
Xiangxue Pharmaceuticals: Report for the third quarter of 2024
Xiangxue Pharmaceutical (300147.SZ): a net loss of 0.218 billion yuan in the first three quarters.
GeLongHui October 25th | Xiangxue Pharmaceutical (300147.SZ) released the third quarter report for 2024, with the company achieving a revenue of 1.534 billion yuan in the first three quarters, a decrease of 11.26% year-on-year; net income attributable to shareholders of the listed company was -0.218 billion yuan; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -0.205 billion yuan; basic earnings per share -0.3300 yuan.
Does Xiangxue PharmaceuticalLtd (SZSE:300147) Have A Healthy Balance Sheet?
Cybrid Technologies Inc.: Shareholder Silver Splendor Investment intends to reduce its shareholding by no more than 3%; Xiangxue Pharmaceutical: The company and the controlling shareholder received a notice of filing from the China Securities Regulatory C
Cybrid Technologies Inc. shareholders Silver Glory Investment intend to reduce their shareholding by no more than 3%; Shareholders of Pava Co., Ltd., Huayi Xinyuan No.1, Huayi Xinyuan No.2, Huayi Xinyuan No.3 intend to collectively reduce their shareholding by no more than 3%; China XD Electric shareholder General Electric Singapore Company intends to reduce by no more than 3%; Lattice Power shareholders Junlian Chengye, Junlian Huicheng intend to reduce their shareholding by no more than 2%; Tibet Urban Development and Investment's 0.132 billion restricted shares will be released on October 8; Zhongfu Information Inc.'s 34.8516 million restricted shares will be released on October 8; Zhongke Magnetic Technology Co., Ltd.'s 5.2688 million restricted shares will be released on October 8; Xiangxue Pharmaceutical stated that the company and the actual controller because of
Xiangxue Pharmaceutical Co.,Ltd. (SZSE:300147) Looks Inexpensive After Falling 39% But Perhaps Not Attractive Enough
Xiangxue Pharmaceutical Co.,Ltd.'s (SZSE:300147) 29% Dip In Price Shows Sentiment Is Matching RevenuesNo Data
No Data
